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As survival has improved after liver transplantation, with potent immunosup-
pressants like tacrolimus, the quality of life and long-term immunosuppression
have become important factors in addition to acute rejection and graft survival.
There are reports on liver transplant recipients who acquire tolerance.
1 We
identified pediatric liver transplant recipients with successful withdrawal of
immunosuppression who developed tolerance and analyzed the patient charac-
teristics, donor-recipient relationship, immunosuppressant regimens, and prognosis.
From April 1997 to July 2007, 105 pediatric liver transplantation recipients
received tacrolimus-based immunosuppression at Samsung Medical Center,
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Purpose: We identified pediatric liver transplant recipients with successful withdrawal of immunosuppression who
developed tolerance in Korea. Materials and Methods: Among 105 pediatric patients who received liver
transplantation and were treated with tacrolimus-based immunosuppressive regimens, we selected five (4.8%)
patients who had very low tacrolimus trough levels. Four of them were noncompliant with their medication and one
was weaned off of immunosuppression due to life threatening posttransplant lymphoproliferative disorder. We
reviewed the medical records with regard to the relationship of the donor-recipients, patient characteristics and
prognosis, including liver histology, and compared our data with previous reports. Results: Four patients received
the liver transplantation from a parent donor and one patient from a cadaver donor. A trial of withdrawal of the
immunosuppressant was started a median of 45 months after transplantation (range, 14 months to 60 months), and
the period of follow up after weaning from the immunosuppressant was a median of 32 months (range, 14 months
to 82 months). None of the five patients had rejection episodes after withdrawal of the immunosuppression; they
maintained normal graft function for longer than 3 years (median, 38 months; range, 4 to 53 months). The
histological findings of two grafts 64 and 32 months after weaning-off of the medication showed no evidence of
chronic rejection.  Conclusion: The favorable markers for successful withdrawal of immunosuppression were 1)
long-term (> 3 years) stable graft function, 2) no rejection for longer than 1 year after withdrawal of immu-
nosuppression, 3) non-immune mediated liver diseases, and 4) pediatric patients.
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INTRODUCTION
MATERIALS AND METHODSSeoul, Korea. Among them, we selected five patients
(4.8%) who had a very low tacrolimus trough level (< 1
ng/mL by Liquid Chromatography-Mass Spectrome-
try/MS). Four of them had frequently refused to take the
immunosuppressive drug; they were interviewed to
confirm the noncompliance. Finally, four patients weaned
due to noncompliance and one patient weaned due to life
threatening posttransplant lymphoproliferative disorder
(PTLD) were enrolled. The median age at transplantation
was three years (range, 8 months to 9 years). The primary
diseases were biliary atresia (n = 2), neonatal hepatitis of
unknown cause (n = 1) and hepatocellular carcinoma (n =
2). Four patients received living-related liver transplan-
tation from their parent and one patient received a cadaver
transplant. All five patients underwent immunosuppression
induced with a steroid and tacrolimus regimen during the
early stage of liver transplantation and were maintained on
tacrolimus-based immunosuppression. Monitoring of graft
function was followed by blood tests to assess liver function.
In cases of abnormal findings in the blood tests,  suspicion
of rejection, a liver biopsy was performed.
We reviewed the medical records and analyzed the
clinical characteristics of the patients who discontinued
immunosuppression, and retrospectively evaluated the
immunologic relationship with their donor (blood type),
immunologic status of a specific virus at pre-transplan-
tation [Ebstein-Barr Virus (EBV), cytomegalovirus
(CMV)], time between transplantation and immunosup-
pressant withdrawal, follow-up period after immunosup-
pressant withdrawal, episodes of rejection, and graft
function. In addition, we attempted to confirm their
histological graft status by performing a liver biopsy in
two of the patients 64 and 32 months after withdrawal of
immunosuppression. 
Four patients received the liver transplantation from a parent
donor and one patient from a cadaver donor. The immu-
nosuppression regimen was steroid and tacrolimus
treatment for a median of six months (range, 2 months to 9
months) after transplantation, followed by maintenance
with tacrolimus for a median of 38 months (range, 4
months to 53 months) (Fig. 1). During the maintenance
period, all patients had stable liver function. Three patients
were treated with pulse steroid therapy and dose up tacroli-
mus therapy when there was suspicion of acute rejection;
two patients were confirmed to have acute rejection by
liver biopsy within a month after transplantation. None of
the five patients had rejection episodes for over 1 year
(range, 14 months to 82 months) after withdrawal of the
immunosuppression.
Among the five cases, there were ABO blood type-iden-
tical grafts in three cases and compatible grafts in two.
Three patients were EBV high-risk (EBV seronegative
recipients from EBV seropositive donor); one of them
developed life threatening gastrointestinal PTLD and was
weaned off immunosuppression 14 months post-trans-
plantation. All five patients were CMV IgG positive pre-
transplantation; there were no complications associated
with CMV infection throughout the follow-up after trans-
plantation (Table 1). 
A trial of withdrawal of immunosuppressant was started
a median of 45 months after transplantation (range, 14
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RESULTS
Table 1.Characteristics of the Subjects
Case 
Diagnosis Sex
Age at 
Donor
Blood type EBV risk Pre LT CMV 
No. transplantation (R/D) group status (IgG / IgM)
1 Biliary atresia F 2 yrs Father O+ / O+ (identical) High (± / -)
2 Neonatal hepatitis M 8 months Mother B+ / O+ (compatable) High (+ / -)
3 Biliary atresia M 3 yrs Father A+ / O+ (compatable) Low (+ / -)
4 HCC (HBV) M 9 yrs Father B+ / B+ (identical) High (+ / -)
5 HCC (HBV) M 8 yrs Cadaver O+ / O+ (identical) Low (+ / -)
HCC, hepatocellular carcinoma; R, recipient; D, donor, EBV, Ebstein-Barr Virus; CMV, cytomegalovirus. 
EBV high-risk group: EBV-seronegative patients receiving allograft from EBV-seropositive donors. 
EBV low-risk group: EBV- seropositive recipient or EBV-seronegative patients receiving allograft from EBV-seronegative donors.
Fig. 1. Immunosuppressant regimens and withdrawal process.months to 60 months), and the period of follow up after
weaning from the immunosuppressant was a median of 32
months (range, 14 months to 82 months). None of the five
patients had rejection episodes after withdrawal of immu-
nosuppression; four of them maintained normal graft
function for longer than 3 years (median, 38 months;
range, 4 to 53 months) (Table 2). There was no case of an
immune-mediated primary liver disease. Two of the four
noncompliant patients (patient 1 and 3) were intentionally
weaned from their medication. The main reason for
weaning off the immunosuppression was parents’ anxiety
about the complications from immunosuppression therapy.
The other two noncompliant patients (patient 4 and 5) had
taken the medication irregularly. These two older children
refused to take the life-long medication. 
We compared these five patients with previous reports
to determine the favorable clinical markers and selection
criteria for discontinuation of immunosuppression (Table
3). Devlin, et al.
2 and Takatsuki, et al.
3 reported on the
withdrawal of immunosuppression, including pediatric
liver transplant recipients, and analyzed the favorable
markers for successful withdrawal of immunosuppression
and the selection criteria for elective weaning. The five
patients reported here had non-immune mediated liver
disease, long-term maintenance of normal graft function
without rejection and were all pediatric recipients. Exclud-
ing the one patient with PTLD, four patients attempted to
wean the immunosuppressant treatment two years post-
transplantation. 
We performed a liver biopsy in two of our patients at 64
months and 32 months after withdrawal of the immu-
nosuppressant to rule out chronic rejection in spite of their
normal liver function. The histological findings of their
grafts showed normal hepatic architecture without any
evidence of acute cellular or chronic rejection (Fig. 2).
Tolerance is defined as the clinical situation when a graft
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DISCUSSION
Table 2.Outcome after Weaning of Immunosuppression
Cause of IS  Maintenance
Time between  Follow-up
Rejection* The last
Case No.
withdrawal IS
LT and  after IS 
(n)
AST / ALT / GGT 
weaning withdrawal (U/L)
1 Noncompliance Tacrolimus 60 months 64 months 0 28 / 25 / 10
2 PTLD Tacrolimus 14 months 82 months 1  33 / 26 / 32
3 Noncompliance Tacrolimus 60 months 32 months 1 23 / 14 / 24
4 Noncompliance Tacrolimus 45 months 14 months 0 28 / 17 / 12
5 Noncompliance Tacrolimus 41 months 29 months 0 21 / 12 / 16
IS, immunosuppressant; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase.
*Rejection before weaning of immunosuppression.
Table 3.Comparison of Favorable Clinical Markers for Withdrawal of Immunosuppression
Suggested factors for withdrawal in the previous studies Subjects included in this study
Author Favorable markers  Case1 Case2 Case3 Case4 Case5 %
> 5 years post-LT O X O X X 40
Devlin, et al. Non-immune mediated liver disorders O O O O O 100
Incidence of early rejection (n) 0 1 1 0 0 -
> 2 years post-LT O X O O O 80
Long-term normal graft function O O O O O 100
Takatsuki, et al. > 1 year without rejection after withdrawal O O O O O 100
LDLT O O O O X 80
Pediatric case O O O O O 100
LDLT, living-donor liver transplantation.
Fig. 2. Liver histologic finding in one patient at 32 months after withdrawal of the
immunosuppressant. Hepatic lobular architecture is well preserved showing
focal balooning degeneration. Portal space displays intact bile ducts with no
inflammatory infiltrate. Mild periportal fibrosis is found (original magnification ×
200, Masson Trichrome).maintains stable function without the need for chronic
immunosuppression;
4 it occurs more frequently in liver
allografts than with other solid organ transplantation.
Some reports support elective immunosuppressive drug
weaning for selected liver transplant recipients.
1 It is
thought that donor cell chimerism is associated with donor
specific tolerance and allograft acceptance. Studies report-
ing on the possibility of these hypotheses have not revealed
the exact mechanism underlying tolerance.
5-7 Thomson, et
al.
4 attempted to evaluate the validity of immunologic and
biologic tests that correlated with and were predictive of a
state of tolerance. They analyzed dendritic cell types,
cytokine secretion, donor specific antibody prevalence, and
cytokine genotypes, however, failed to identify any clini-
cally useful markers. Mazariego, et al.
8 suggested that an
increased ratio of plasmacytoid dendritic cell to myeloid
dendritic cell was a significant factor for achieving opera-
tional tolerance. Therefore, the mechanism underlying
tolerance is not known, and there have been no large-scale
studies of elective weaning off of immunosuppressant
treatment. There are only a limited number of studies on
accidentally weaned noncompliant patients and withdra-
wal of immunosuppressant due to severe infection or
PTLD, or small groups of selectively chosen patients for
elective weaning at certain centers.
1-3,9-14
Mazariego, et al.
12 reported that azathioprine/prednisone-
and tacrolimus-based treatment of patients were more
likely to be off drugs at one year after transplantation com-
pared to cyclosporine treated patients, and Takatsuki, et al.
3
suggested that the graft survival was better in patients who
received a living-related donor transplantation. Lerut, et al.
1
reviewed reports on the withdrawal of immunosuppression
and found that immunosuppression withdrawal is possible
in 19.4% of transplant recipients, and that the common
favorable clinical markers were: 1) an age > two years post
liver transplantation, 2) a low incidence of rejection, 3) non-
immune mediated liver disease, and 4) minimal immu-
nosuppression. Most of the prospective elective withdra-
wal studies included patients followed for longer than two
years. However, Eason, et al.
10 enrolled patients with less
than six months of follow-up, and only one of their eighteen
patients was weaned off the immunosuppression success-
fully. Therefore, it remains unclear when immunosup-
pression can safely be withdrawn.
Some reports have raised concerns about chronic rejection
after withdrawal of immunosuppression.
1,15 Koshiba, et al.
16
reported that liver biopsy after complete withdrawal of the
immunosuppressant revealed changes of the bile duct and
fibrosis. However, there were no such findings in our study.
The five patients included in this study had long-term (> 3
years) stable graft function, no rejection for more than 1
year after withdrawal of immunosuppression, non-immune
mediated liver diseases, and were all pediatric cases; all of
these factors are favorable markers, according to previous
reports. Although a small number of patients were studied,
this is the first report on tolerance in pediatric liver trans-
plant recipients in Korea after withdrawal of immunosup-
pression. To improve the quality of life for liver transplant
recipients, confirmation of our findings with a multicenter
trial is now needed to determine patient factors, clinical
timing and biological markers associated with successful
immunosuppressant withdrawal. 
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